TheEdgeResearch
Home / Stocks / FNAM

Evolutionary Genomics, Inc. (FNAM)

OTC Healthcare Biotechnology
$0.00 ▲ +0.00%
Market Cap
$1,331
Sector
Healthcare
Industry
Biotechnology
Beta
-0.12
52-Wk Range
0.0002-0.45
CEO
Steven Bryan Warnecke
Country
US
Currency
USD

Evolutionary Genomics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Castle Rock, CO, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $1,331. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of -0.12 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.00
Price / Sales
0.00
Price / Book
-0.00
EV / EBITDA
-3.47
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-2.39
Current ratio
3.92
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
2
IPO date
2011-04-08
Headquarters
Castle Rock, CO, US
About Evolutionary Genomics, Inc.

Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. The company is based in Castle Rock, Colorado.

Comparable companies

Evolutionary Genomics, Inc. is most often compared with the following Healthcare names:

CLABFDOSEFENZNHLYKLIFDREPCFRSCFSIGYSRNETDSGF
More research on FNAM
FNAM technical analysis FNAM TheEdge Score Compare against peers
Open full interactive analysis & DCF →